UNIGE document Scientific Article
previous document  unige:108162  next document
add to browser collection
Title

Somapacitan, a once-weekly reversible albumin-binding GH derivative, in children with GH deficiency: A randomized dose-escalation trial

Authors
Battelino, Tadej
Rasmussen, Michael Højby
De Schepper, Jean
Zuckerman-Levin, Nehama
Gucev, Zoran
Sävendahl, Lars
Zumsteg, Urs
Collaboration
Published in Clinical Endocrinology. 2017, vol. 87, no. 4, p. 350-358
Abstract To evaluate the safety, local tolerability, pharmacodynamics and pharmacokinetics of escalating single doses of once-weekly somapacitan, a reversible, albumin-binding GH derivative, vs once-daily GH in children with GH deficiency (GHD).
Keywords ChildChildPreschoolDwarfismPituitary/blood/drug therapyFemaleGrowth Hormone/analogs & derivatives/pharmacokinetics/therapeutic useHuman Growth Hormone/analogs & derivatives/blood/deficiencyHumansInsulin-Like Growth Factor Binding Protein 3/bloodInsulin-Like Growth Factor I/metabolismMale
Identifiers
PMID: 28656605
Full text
Article (Author postprint) (373 Kb) - document accessible for UNIGE members only Limited access to UNIGE
Structures
Research group Diabète et métabolisme (178)
Citation
(ISO format)
BATTELINO, Tadej et al. Somapacitan, a once-weekly reversible albumin-binding GH derivative, in children with GH deficiency: A randomized dose-escalation trial. In: Clinical Endocrinology, 2017, vol. 87, n° 4, p. 350-358. https://archive-ouverte.unige.ch/unige:108162

11 hits

0 download

Update

Deposited on : 2018-09-21

Export document
Format :
Citation style :